The result was announced on Sunday, 13 November 2011.
Meanwhile, the BSE Sensex was up 179.46 points, or 1.04%, to 17,372.28.
On BSE, 14,000 shares were traded in the counter compared with average volume of 37,000 shares over the past two weeks.
The stock hit a high of Rs 516.90 and a low of Rs 512 so far during the day.
Sun Pharmaceutical Industries' (Sun Pharma) said Israel-based Taro Pharmaceutical Industries (Taro) became a subsidiary of the company on 20 September 2010. Hence the consolidated result is not comparable with the corresponding quarter of the precious year.
On a consolidated basis, Sun Pharma's employees cost surged 87.31% to Rs 272.69 crore in Q2 September 2011 over Q2 September 2010. Consumption of materials spurted 55.95% to Rs 436.69 crore in the same period.
In Q2 September 2011, Sun Pharma's India-branded generic sales grew by 18% to Rs 705 crores, excluding third party manufacturing business, compared with Q2 September 2010.
In Q2 September 2011, US-finished dosage sale were reported at $175 million. International formulation sales were reported at $56 million. Earnings Before Interest Taxes Depreciation and Amortization (EBITDA) margin were reported at 41%.
According to Dilip Shanghvi, Chairman and Managing Director of the company, Performance delivered this quarter and in the first half, though partly aided by the exchange rate movement, is a clear reflection of the steady effort made across all parts of our business towards long term sustainable growth and profitability. India business maintains the growth in prescription share with our key customers. In the US and other international markets, work continues on enriching the product pipeline and on strengthening the quality and regulatory processes.
Sale of branded prescription formulations in India was at Rs 705 crore in Q2 September 2011, registering a growth of 15% over Q2 September 2010 and accounting for 37% of total sales.
Sun Pharma holds 4.4% market share in the highly competitive pharma market, as per latest AIOCD report. Overall, the company is now ranked number one, based on share of prescriptions with 7 classes of specialists: psychiatrists, neurologists, cardiologists, ophthalmologists, orthopedics, gastroenterologists and consulting physicians.
The company said 10 key products were launched during the quarter taking the total to 17 for the first half.
Sun Pharmaceutical Industries is an international specialty pharma company, with a large presence in the US and India, and a footprint across 40 other markets. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology and orthopedics.